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Topical Cholecystokinin Depresses Itch-Associated
Scratching Behavior in Mice
Shoko Fukamachi1, Tomoko Mori1, Jun-Ichi Sakabe1, Noriko Shiraishi1, Etsushi Kuroda2, Miwa Kobayashi1,
Toshinori Bito3, Kenji Kabashima4, Motonobu Nakamura1 and Yoshiki Tokura1,5
Cholecystokinin (CCK) serves as a gastrointestinal hormone and also functions as a neuropeptide in the central
nervous system (CNS). CCK may be a downregulator in the CNS, as represented by its anti-opioid properties.
The existence of CCK in the peripheral nervous system has also been reported. We investigated the suppressive
effects of various CCKs on peripheral pruritus in mice. The clipped backs of ICR mice were painted with CCK
synthetic peptides and injected intradermally with substance P (SP). The frequency of SP-induced scratching
was reduced significantly by topical application of sulfated CCK8 (CCK8S) and CCK7 (CCK7S), but not by
nonsulfated CCK8, CCK7, or CCK6. Dermal injection of CCK8S also suppressed the scratching frequency,
suggesting that dermal cells as well as epidermal keratinocytes (KCs) are the targets of CCKs. As determined
using real-time PCR, mRNA for CCK2R, one of the two types of CCK receptors, was expressed highly in mouse
fetal skin–derived mast cells (FSMCs) and moderately in ICR mouse KCs. CCK8S decreased in vitro compound
48/80-promoted degranulation of FSMCs with a transient elevation of the intracellular calcium concentration.
These findings suggest that CCK may exert an antipruritic effect via mast cells and that topical CCK may be
clinically useful for pruritic skin disorders.
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INTRODUCTION
Itch or pruritus is an unpleasant cutaneous sensation
associated with the immediate desire to scratch (Ikoma
et al., 2006; Steinhoff et al., 2006). Histamine was long
considered the only mediator of pruritus, but this assumption
has changed dramatically in the past two decades. Peripheral
itch can be evoked in the skin either directly, by mechanical
and thermal stimuli, or indirectly, through chemical media-
tors (Ikoma et al., 2006). Itch may also be generated in the
central nervous system (CNS) independent of peripheral
stimulation. Different puritic diseases involved different itch
mediators, including histamine, neuropeptides, proteases,
prostaglandins, serotonin, acetylcholine, cannabinoids,
opioids, bradykinins, cytokines, biogenic amines, neuro-
transmitters, and ion channels (Steinhoff et al., 2006).
Neuromediators such as neuropeptides and neurotrophins,
as well as their receptors, have an important role in peripheral
itch. Neuropeptides, as represented by pruritogenic neuro-
peptide substance P (SP), are produced by sensory nerves, but
they can also be elaborated by epidermal keratinocytes (KCs),
mast cells, fibroblasts, and other cutaneous immunocompe-
tent cells (Ohkubo and Nakanishi, 1991; Scholzen et al.,
1998). Many other mediators are also produced by and
secreted from skin-constituent cells in close contact to sensory
nerves (Steinhoff et al., 2006). They can activate and sensitize
pruritic nerve endings and even modulate their growth, as do
nerve growth factors and chemorepellents (Yamaguchi et al.,
2008; Yosipovitch and Papoiu, 2008). As for the receptor
system, it is notable that KCs, mast cells, and fibroblasts
express neurokinin-1 receptor (Ohkubo and Nakanishi, 1991;
Scholzen et al., 1998), which is the receptor for SP. These
complicated neurophysiological interactions yield itch and
render its therapeutic control difficult.
Cholecystokinin (CCK) is a peptide hormone in the
gastrointestinal tract (Dufresne et al., 2006), but it also serves
as a neuropeptide (Ma et al., 2006). Among neuropeptides,
CCKs are most abundantly present in the CNS and invo-
lved in numerous physiological functions such as
anxiety, depression, psychosis, memory, and feeding behavior
(Dufresne et al., 2006). CCKs also have anti-opioid properties
in the CNS (Pommier et al., 2002; Mollereau et al., 2005) and
exert a nociceptive effect in the spinal cord (Wiesenfeld-
Hallin et al., 1999). Furthermore, their existence in the
peripheral nervous system has been reported (Moriarty et al.,
1997). In various CCKs, sulfation of the tyrosine at position 7
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from the C-terminus is a posttranslational modification that
makes them biologically active peptides (Ma et al., 2006).
Varying lengths of CCKs with or without sulfate have been
studied for their activities as gastrointestinal hormones
(Bonetto et al., 1999) and as CNS players (Rehfeld et al.,
2007). Two types of CCK receptors have been identified:
CCK1R (CCK-A receptor) and CCK2R (CCK-B receptor).
CCK1R usually requires sulfated CCKs. CCK2R affords a
binding site to both sulfated and nonsulfated ligands, but
nonsulfated CCKs have affinities that are decreased 10- to
50-fold (Dufresne et al., 2006). CCKs exert their biological
functions by interacting with CCK receptors located on
multiple target cells in the CNS and on peripheral nerve
endings (Dufresne et al., 2006; Rehfeld et al., 2007; Zheng
et al., 2009). In the brain, sulfated CCK8 (CCK8S) is most
abundant (Rehfeld et al., 2007) and possesses one of the
strongest endogenous anti-opioid properties (Ma et al., 2006).
Prolonged opioid exposure increases the expression of CCKs
and CCK2R in the CNS, where CCK8S negatively modulates
opioid responses and maintains homeostasis of the opioid
system (Pommier et al., 2002; Agnes et al., 2008). Thus, it
seems that CCKs are downregulators of opioid-mediated
pruritus in CNS. However, the function of CCKs, the
distribution of CCK receptors in the skin, and their effects
on peripheral pruritus remain unelucidated (Ma et al., 2006).
In this study, we investigated the antipruritic effects of
different lengths of CCKs with or without sulfate, which were
topically applied onto the skin of mice. Results suggest that
CCKs are capable of reducing SP-induced scratching at least
by affecting the function of mast cells. Our findings may lead
to the development of previously unreported antipruritic
strategies.
RESULTS
Depressive effects of topical application of CCKs on
SP-induced itch-associated response
We tested various CCKs for their ability to suppress scratching
behavior induced by intradermal SP injection in ICR mice
(Andoh et al., 2001). We first examined the effect of
percutaneously applied CCK on the response. Because
CCK8S has an inhibitory ability in the CNS (Pommier et al.,
2002; Dufresne et al., 2006) and gastrointestinal tract
(Miyasaka et al., 2004), CCK8S and the other CCK constructs
consisting of smaller amino acids with or without sulfate
(Table 1) were tested for their antipruritic activities. ICR mice
were painted with various CCKs on the clipped, tape-stripped
rostral part of the back skin (B1.8 cm2) and then injected
with SP intradermally at the CCK-painted site.
The topical application of CCK8S significantly reduced the
scratching frequency, as compared with the nonapplied
control (Figure 1a). Sulfated CCK7 (CCK7S) also reduced the
scratching frequency, to a level comparable to that with
CCK8S, whereas nonsulfated CCK8, CCK7, and CCK6 had no
ability to suppress scratching. These results showed that CCKs
have an antipruritic ability, and CCK constructs bearing
sulfation of position 7 are required for the ability to suppress
the scratching behavior. In this itch-associated-scratching
model, we also administered CCK8S intradermally together
with SP to mice. The scratching frequency induced by SP was
profoundly suppressed by the simultaneous injection of
CCK8S (Figure 1b). When the time course of effects induced
by CCK8S was examined, both topical application (Figure 1c)
and intradermal injection (Figure 1d) of CCKS reduced
the scratching frequency at intervals of 0–5 minutes and
5–10 minutes.
These findings raised the possibility that epidermal and
dermal cells participating in the development of itch are
affected by CCKs.
Table 1. Amino acid sequences of CCK and its
constructs
Sulfated
CCK8 (CCK8S)
Asp–Tyr (SO3)–Met–Gly–Trp–Met–Asp–Phe–NH2
Nonsulfated
CCK8 (CCK8)
Asp–Tyr–Met–Gly–Trp–Met–Asp–Phe–NH2
Sulfated
CCK7 (CCK7S)
Tyr (SO3)–Met–Gly–Trp–Met–Asp–Phe–NH2
Nonsulfated
CCK7 (CCK7)
Tyr–Met–Gly–Trp–Met–Asp–Phe–NH2
Nonsulfated
CCK6 (CCK6)
Met–Gly–Trp–Met–Asp–Phe–NH2
Abbreviation: CCK, cholecystokinin.
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Figure 1. Suppression of substance P (SP)-induced itch by percutaneous
application or intradermal injection of cholecystokinins (CCKs). (a) ICR mice
were painted on the clipped skin with CCKs (0.5 nmol per site) and injected
intradermally with SP (100 nmol per site). The group depicted with ‘‘()’’
represents mice injected with vehicle (acetone/olive oil) alone. The numbers of
mice were as follows: CCK (—), n¼ 12; CCK8S, n¼10; CCK8, n¼ 6; CCK7S,
n¼6; CCK7, n¼3; and CCK6, n¼4. (b) ICR mice were injected intradermally
with SP or with SP and CCK8S. Each bar represents the mean of scratches per
20 minutes. CCK (), n¼ 5 and CCK8S, n¼ 8. (c) Time course of scratching
frequency in mice untreated (n¼12) or topically administered CCK8S (n¼ 10).
(d) Time course of scratching frequency in mice untreated (n¼ 5) or
intradermally injected with CCK8S (n¼ 8). CCK7, nonsulfated CCK7; CCK8,
nonsulfated CCK8; CCK7S, sulfated CCK7; CCK8S, sulfated CCK8.
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CCK2R expression in KCs and mast cells
Both KCs and mast cells are the possible targets of CCKs in
the suppression of SP-induced pruritus. It is known that KCs
express the receptors for itch-related molecules, neurokinin-1
receptor for SP, H1 receptor for histamine, and protease-
activated receptor-2 for tryptase (synthetic agonist, SLIGRL-
NH2). Mast cells are well known to possess neurokinin-1
receptor (Scholzen et al., 1998; Liu et al., 2006). We investi-
gated the expression of the CCK receptors CCK1R and CCK2R
in KCs and mast cells. Primary cultures of KCs from ICR mice
and fetal skin–derived mast cells (FSMCs) were collected, and
mRNAs for CCK1R and CCK2R were quantitated by real-time
PCR, RT-PCR, and western blotting analyses. The two types
of cells expressed both CCK1R and CCK2R at the mRNA
and protein levels (Figure 2). When the expression levels of
real-time PCR analysis were normalized with the b-actin
level, the two receptors were more highly expressed in
FSMCs than in KCs.
In a preliminary DNA microarray analysis of normal human
epidermal KCs, we investigated the levels of gene expression
from stimulation with SP (106 M), histamine (10mg ml1),
or SLIGRL-NH2 (100 nM) under high calcium (0.6 mM) concen-
tration. The CCK2R expression by SP-stimulated KCs was most
elevated; its level was 28.67 times that of the control (Supple-
ment Data online). Such an increased CCK2R expression was
not observed with histamine or SLIGRL-NH2. This observation
suggested that CCK2R has an important role in the suppression
of SP-stimulated KCs. To determine the effect of SP on KCs, ICR
mouse KCs were incubated with SP for 30 minutes to 24 hours,
and the expression of CCK2R and CCK1R was analyzed
by western blotting. CCK2R was detected with antibodies as a
78 kDa band (Morisset et al., 2003) and increased in KCs
exposed to SP for 5 or 6 hours (Figure 3a). By contrast, CCK1R
expression was not augmented by SP (Figure 3b). Thus, the
expression of some receptors for CCK is enhanced by SP,
depending on the receptor.
Suppression of FSMC degranulation by CCK8S with transient
elevation of intracellular calcium
The above findings suggested that CCKs bind to CCK2R on
KCs and mast cells and downmodulate their itch-related
biological functions. Given that the level of CCK2R expres-
sion was higher in FSMCs than in KCs and the application
of CCKs immediately exerted its inhibitory effects on the
scratching behavior, it is possible that CCKs directly affect
mast cells. We therefore focused on mast cells as the primary
target. The addition of compound 48/80 induced degranu-
lation of FSMCs (Figure 4a). This promoted degranulation of
FSMCs, which was significantly inhibited by CCK8S at 108
or 107 M concentration.
To test whether CCK8S evokes signal transduction in
mast cells, we measured the intracellular calcium using
confocal recording. The fluorescence intensity of 15 cells
positively responding on addition of CCK8S was monitored
with computerized color change on a display using a digital
image processing system. The mast cells exhibiting green
fluorescence of Fluo-4-AM at any time point between 40 and
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Figure 2. CCK-A receptor (CCK1R) and CCK-B receptor (CCK2R) mRNA
expression in keratinocytes and mast cells. Cultured ICR mouse keratinocytes
(a) and fetal skin–derived mast cells (FSMCs) (b) were examined for the
expression of mRNAs for CCK1R and CCK2R using real-time PCR and RT-PCR
and for the expression of their proteins using western blotting analysis.
Data are expressed as the amount of expression relative to b-actin.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as
control for western blotting.
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Figure 3. Western blotting of CCK-A receptor (CCK1R) and CCK-B receptor (CCK2R) in mouse keratinocytes stimulated with substance P (SP). ICR mouse
keratinocytes were incubated with SP (108 M) for 0.5–24 hours and harvested at each time point. The expression levels of CCK2R (a) and CCK1R (b) were
analyzed by western blotting. NIH/3T3 whole lysates were used as positive control. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as control
for western blotting and exhibited similar intensities in the samples cultured for 0–24 hours. The intensity of each band was subjected to densitometric analysis
and expressed as density relative to the nontreated control (0).
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80 seconds after CCK8S addition were defined as positively
responding cells (Figure 4b and c); these are marked with
a yellow circle in Figure 4b. The addition of CCK8S to the
FSMC culture induced a prompt rise of calcium that persis-
ted for more than 2 minutes and then gradually declined,
indicating that CCK8S induces signaling via CCK2R in mast
cells. The percentage of responding FSMCs was determined
from the fluorescence traces of all cells. As shown in Figure
4b, in which circles and squares represent CCK8S-responding
and nonresponding FSMCs, respectively, 45% (16 of 36 cells)
of FSMCs were typically activated by CCK8S.
DISCUSSION
Despite their original name of cholecyst stimulators, CCKs have
been known to serve as CNS modulators (Dufresne et al., 2006)
and CCK8S downmodulates opioid responses (Pommier et al.,
2002; Agnes et al., 2008). As suggested in our present study,
CCKs may also have a function of downmodulator in the
peripheral itch. The topical application of CCKs suppressed the
itch-related scratching behavior evoked by SP injection. The
expression of CCK2R, but not CCK1R, in murine and human
KCs was markedly enhanced by exposure to SP. It is likely that
CCK2R, whose expression is augmented by SP, has a down-
regulatory role in the excess peripheral itch.
Among the CCK constructs consisting of different numbers
of amino acids with or without sulfate, CCK8S and CCK7S, but
not CCK8, CCK7, or CCK6, exerted an antipruritic action.
Therefore, in a comparison between CCK8S and CCK8 and
between CCK7S and CCK7, sulfation of position 7 is required
for the ability to suppress the scratching behavior. This is in
accordance with the observation that CCK8S has an anxiogenic
effect (Harro, 2006), a depressant effect, and an anti-opioid
effect (Noble et al., 1999), but the effects of CCK are limited by
desulfation of the tyrosine (Tokunaga et al., 1993).
Although the exact mode of antipruritic action of CCKs
is still speculative, some informative observations were
obtained from the study. Both percutaneous application and
dermal injection were effective routes for CCK8S in suppres-
sing itch, suggesting that epidermal and/or dermal constitu-
ents are the targets of CCKs. Furthermore, the administration
of CCK8S rapidly inhibited the SP-induced itch. We thus
investigated the mechanism of CCK suppression of itch in
in vitro studies, focusing on mast cells. CCK8S significantly
reduced the degranulation of FSMCs with elevation of
intracellular calcium concentration, suggesting that mast
cell degranulation is inhibited by CCK8S through CCK2R.
Alternatively, or additionally, KCs are possibly involved in
CCR action. KCs are thought to mediate pruritus by releasing
inflammatory mediators and neurotrophins. Therefore, the
antipruritic effect of CCK8S on KCs, if any, seems to need a
time lag to operate. As the therapeutic action of topical
CCK8S is rapid, mast cells may be more likely targeted by
CCK8S than KCs. The high expression of CCK2R in mast
cells further supports the notion that mast cells are sensitive
to CCKs. However, SP was reported to cause scratching
behavior in both mast cell–deficient and wild-type mice
(Hossen et al., 2003), suggesting a mast cell-independent
mechanism of SP-evoked itch. Given this observation, it is
possible that another skin constituent, such as the sensory
nerves, is affected by CCKs. The target cells and the actions of
CCK8S on them warrant elucidation in the future.
The antipruritic effects of CCK8S and CCK7S on this mouse
itch model may afford a therapeutic use for the CCKs for the
treatment of skin diseases with peripheral itch. Given that the
major target of CCKs is mast cells, urticaria, atopic dermatitis,
contact dermatitis, and other types of eczematous dermatitis
would be successfully treated with CCKs topically applied to the
skin. The therapeutic effects of CCKs on peripheral itch may
shed light on the mechanisms underlying the physiological
regulation of itch, and it is notable that CCKs have potential as a
topical drug for pruritic skin diseases.
MATERIALS AND METHODS
Animals
Female ICR mice were obtained from KBT Oriental (Tosu, Japan).
These mice were maintained in the Laboratory Animal Research
Center of the University of Occupational and Environmental Health
under specific-pathogen-free conditions and used at the age of 6–8
weeks. All animal experiments were performed according to the
guidelines approved by our university for the care and use of animals.
Reagents
SP, CCK8S, nonsulfated CCK8, CCK7S, and nonsulfated CCK6 were
purchased from the Peptide Institute (Osaka, Japan). Nonsulfated
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Figure 4. Suppression of fetal skin–derived mast cell (FSMC) degranulation by sulfated CCK8 (CCK8S) with transient intracellular calcium increase. (a) FSMCs
were incubated with or without CCK8S in the presence of compound 48/80 (C48/80; 50mg ml1) for 15 minutes. Supernatants and cell lysates were incubated
with p-nitrophenyl-N-acetyl-b-D-galactosaminide, and b-hexosaminidase (b-Hex) release was determined as the ratio between activity in the supernatant
and cell lysate, multiplied by 100. (b) FSMCs were loaded with Fluo-4-AM (green) and stained for CD117 (c-kit, red). The percentage of CCK8S-responding
FSMCs was determined from the fluorescence traces of all cells. Circles represent responding FSMCs and squares represent nonresponding FSMCs.
Bar ¼20 mm. (c) The addition of CCK8S to FSMC culture induced an increase in intracellular calcium level.
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CCK7 was purchased from Funakoshi (Tokyo, Japan). Compound 48/
80 was purchased from Sigma (St Louis, MO).
Itch-associated scratching behavior and topical application
of CCKs
The hair was clipped over the rostral part of the each mouse’s back 1
or 2 days before the experiment. Before behavioral recording, each
animal (four per observation) was put into an acrylic cage
(18 23 11 cm) for at least 1 hour for acclimation. An intradermal
injection of SP (100 nmol in 50ml of physiological saline per site)
induced scratching of the skin around the injected site with the
hindpaws (Andoh et al., 2001). CCKs were topically applied in two
ways: percutaneous application and intradermal injection. For
percutaneous application, the shaved back skin was stripped with
Scotch tape (3 M) six times on the day before the experiment
(Nishijima et al., 1997). The clipped backs of the mice were painted
(1.8 cm2, 1.5 cm in diameter) with 20 ml CCK (0.5 nmol per site) in
acetone/olive oil (3:1) 3–4 minutes before the SP injection (100 nmol
per site). For intradermal application, mice were injected intrader-
mally with CCK (0.5 nmol per site in 20 ml physiological saline),
followed immediately by SP injection at the same site (100 nmol per
site). Immediately after treatment, the animals were put back into the
same cage and their behavior was videotaped for 40 minutes using a
digital video camera (Andoh et al., 2001). Using the video, the
frequency of scratching toward the injected site by the hindpaws was
recorded for the first 20 minutes.
Murine KCs
The skin of ICR newborn mice was peeled within 24 hours after birth
and incubated with 0.05% collagenase (collagenase from Clostri-
dium histolyticum type 2; Sigma) for 2 days at 37 1C in a 5% CO2
atmosphere. Epidermal sheets were collected and suspended in
culture medium. Cell suspension was plated into six-well plates
(Corning Glass Works, Corning, NJ) and grown to subconfluence in
CnT-07 medium (Funakoshi).
Murine mast cells
The method for preparation of murine FSMCs has been described
previously (Yamada et al., 2003). Day 14 fetal skin was dissociated by
0.25% trypsin for 20 minutes at 37 1C in Hank’s balanced salt solution
(Gibco, Carlsbad, CA). Erythrocytes were lysed using RBC-lysing buffer
(Sigma) and, after washing, cells were resuspended in complete RPMI,
which is RPMI-1640 (Gibco) supplemented with 5% fetal bovine
serum (Gibco), 1% nonessential amino acids (Gibco), 1% sodium
pyruvate (Gibco), antibiotic/antimycotic (Invitrogen, Carlsbad, CA),
and 0.1% 2-mercaptoethanol (Gibco). Fifty milliliters of the cell
suspension in each 175 cm2 75-flask (Corning Glass Works) was
cultured in the presence of 20 ng ml1 recombinant mouse IL-3
(Invitrogen) and 20 ng ml1 recombinant mouse stem cell factor
(Biosource, Camarillo, CA) at 37 1C without changing the medium.
Nonadherent and loosely adherent cells were harvested. The cells
were centrifuged and resuspended in RPMI, layered on 40% Percoll
(GE Healthcare, Buckinghamshire, England), and centrifuged at room
temperature. The cell pellet at the bottom was used as FSMCs. For
flowcytometric analysis, cells were stained with phycoerythrin-
conjugated anti-mouse FceRI (eBioscience, San Diego, CA) and Alexa
Fluor 700-conjugated anti-mouse CD117 (c-kit; eBioscience) for
20 minutes on ice, washed twice, and then resuspended with FACS
buffer. Flow cytometric analysis was performed with FACS Canto (BD,
Franklin Lakes, NJ) and FlowJo software (TreeStar, San Carlos, CA). The
purity of FSMCs was 95%, as determined by both FceRI and CD117
positivity by flow cytometry.
Real-time quantitative RT-PCR analysis
Total RNA was extracted from the cell pellet using the PureLink RNA
Mini Kit (Invitrogen). cDNA was reverse transcribed from total RNA
samples using the TaqMan Reverse Transcription reagents (Applied
Biosystems, Carlsbad, CA). mRNA expression was quantified by real-
time PCR using SYBR Green Dye (PE Biosystems, Foster City, CA)
with an ABI PRISM 7000 Sequence Detection System (Applied
Biosystems) according to the manufacturer’s instructions. Primers
were designed using Primer Bank for the human and murine genes,
and they were constructed by Invitrogen. The sequences are as
follows: murine b-actin: 50-GGCTGTATTCCCCTCCATCG-30 and
50-CCAGTTGGTAACAATGCCATGT-30; murine CCK2R: 50-GATGG
CTGCTACGTGCAACT-30 and 50-CGCACCACCCGCTTCTTAG-30;
and murine CCK1R: 50-CACGCTGGTTATCACGGTG-30 and 50-GC
CCATGAAGTAGGTGGTAGTC-30. The conditions for the real-time
PCR were as follows: 2.0 minutes at 50 1C, 10 minutes at 95 1C, and
then 50 cycles of amplification consisting of 15 seconds at 95 1C and
1 minute at 60 1C. All heating and cooling steps were performed with
a slope of 20 1C per second. Relative expression was calculated
using the delta Ct method.
Western blotting
KCs from ICR mice were stimulated with SP (108 M) in six-well plates
(Corning Glass Works) for 0.5–24 hours, harvested with a rubber
policeman, and subjected to extraction with RIPA buffer (Wako,
Osaka, Japan; 50 mM Tris-HCl (pH8.0), 150 mM sodium chloride,
0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) SDS, and 1.0%
(wt/vol) NP-40 substitute). Protein samples (20 ı`g) were separated by
8% SDS-polyacrylamide gel electrophoresis and electroblotted onto
polyvinylidene difluoride membranes for 2 hours at 180 mA. After
blocking with 5% skim milk solution, the membranes were incubated
with rabbit anti-mouse CCK1R (SC-33220; 1:1,000, Santa Cruz, Santa
Cruz, CA), CCK2R (SC-33221; 1:1,000, Santa Cruz) polyclonal
antibodies, or GAPDH (SC-25887; 1:1,000, Santa Cruz), and the
reaction was detected with horseradish peroxidase–conjugated goat
anti-rabbit IgG (1:3,000, Bio-Rad, Hercules, CA). Immunoblots were
visualized using the ECL Plus Western Blotting Detection Reagents
(GE Healthcare) according to the manufacturer’s protocol. Bands were
quantified by densitometry with the help of a CS Analyzer version 2.0
(ATTO, Tokyo, Japan). NIH/3T3 whole cell lysate (Santa Cruz) was
used as a positive control.
Mast cell degranulation
Degranulation of FSMCs was assessed by b-hexosaminidase assay
(Yamada et al., 2003; Noguchi et al., 2005). FSMCs were washed
with Tyrode’s buffer (Sigma) and resuspended at a concentration of
2 104 cells per well into a 96-well plate. FSMCs were incubated
with or without CCK8S in the presence of compound 48/80
(50 mg ml1) for 15 minutes at 37 1C. The plate was centrifuged for
5minutes, and the supernatants were placed into another 96-well plate.
Cell pellets were resuspended in Tyrode’s buffer containing 0.5% triton
X-100 (Sigma). Supernatants and cell lysates (50ml) were incubated with
100ml of 2.5mM p-nitrophenyl-N-acetyl-b-D-galactosaminide (Sigma),
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dissolved in 0.04 mM citrate buffer (pH 4.5), at 37 1C for 90 minutes. The
reaction was stopped with 100ml of 0.4 M glycine (pH 10.7; MP
Biomedicals, Solon, OH). The plate was read at 405 nm using a 595nm
reference filter in a microplate reader (Bio-Rad). b-Hexosaminidase
release was determined as the ratio between activity in the supernatant
and the cell lysate, multiplied by 100.
Calcium influx determined by confocal imaging
Confocal imaging of cells loaded with fluorescent dyes was
performed using a Zeiss LSM5 pascal (Carl Zeiss, Jena, Germany).
FSMCs were loaded with Fluo-4-AM (Invitrogen; 1mM) at 37 1C for
20 minutes, washed twice, and set aside for at least 40 minutes.
FSMCs were also stained for CD117 (c-kit) with Alexa Fluor
700–conjugated anti-mouse CD117 antibody. The LSM5 multitrack
configuration was used for simultaneous measurement of intracel-
lular calcium concentration (excitation, 488 nm; emission, long-pass
505 nm filter) and the expression of CD117 (excitation, 633 nm;
emission, long-pass 650 nm filter). Images were recorded (usually
recording for 300 seconds) at room temperature, in a 512 512-
pixel format. As stimulants, SP or CCKs were added directly to the
bath as a small drop (10ml; final concentration, 106 M SP and
106 M CCK8S). Image data were analyzed offline using the Zeiss
LSM510 analyzing software (LSM Image Examiner, Carl Zeiss). The
mast cells exhibiting green fluorescence of Fluo-4-AM at any time
point between 40 and 80 seconds after CCK8S addition were defined
as positively responding cells.
Gene-array analysis
Normal human epidermal KCs were cultured with SP (106 M),
histamine (10 mg ml1), and SLIGRL-NH2 (100 nM) for 2 hours and
harvested. For DNA microarray analysis, total RNA was extracted
from Normal human epidermal KCs with the RNeasy Mini Kit
(Qiagen, Valencia, CA). Images were analyzed with the DNASIS
Array (DNA Chip Research, Hitachi Software Engineering, Tokyo,
Japan) according to the manufacturer’s instructions. The results of
DNA microarray analysis of the top and bottom 20 genes with
respect to expression levels induced by SP, histamine, or SLIGRL-
NH2 are shown in the Supplementary Data online.
Statistical analysis
Data were analyzed using an unpaired Student’s t-test. Po0.05 was
considered to be significant.
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